- Home
- About
- About
- Our Team
- Our Strategies
- Our Strategies
- Worldwide Healthcare
- Emerging Markets Healthcare
- Private Investments
- News
- Contact
- Contact
- Eligible Investors
- Investor Login
English
Chinese (Simplified)
English
- More
- Back
Centrexion Therapeutics is a late clinical-stage biopharmaceutical company focused on becoming a leader in identifying, developing and commercializing novel, non-opioid and non-addictive therapies to address the large unmet medical need for the treatment of chronic pain. www.centrexion.com
IMPACT Therapeutics is a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. Impact has assembled one of the most comprehensive DNA damage response (DDR) global pipeline of novel drug candidates generated by in-house discovery efforts and is expanding to other novel synthetic lethality targets to broaden its pipeline.
Founded in 2015, New Horizon Health is a cancer screening market leader, focusing on the design, development and commercialization of cancer screening tests. The company’s vision is to prevent and cure cancer by screening and early detection. The company markets its tests through multiple channels, including hospitals, health checkup centers, insurance companies, pharmacy and online channels. ir.newhorizonbio.com/en
New Frontier Health (NFH) was founded to deliver high quality and comprehensive healthcare services across China, and to capitalize on growth opportunities through organic expansion of the United Family platform, as well as strategic acquisitions. NFH’s investment in UFH will drive accelerated growth to United Family Healthcare through its strategic development and expansion plan designed to grasp the opportunity created by the supply and demand mismatch and changing demographics in China.
Broncus® Medical, Inc. is a healthcare company based in San Jose, CA. The Company’s mission is to deliver navigation, diagnostic & therapeutic technologies to treat patients with lung disease. The Company has a comprehensive intellectual property portfolio with over 75 patents including those issued, licensed, and pending. www.broncus.com